Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas

G. Heller, K. M. Fong, L. Girard, S. Seidl, A. End-Pfützenreuter, G. Lang, A. F. Gazdar, J. D. Minna, C. C. Zielinski, S. Zöchbauer-Müller

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

TSLC1 (tumor suppressor in lung cancer-1, IGSF4) encodes a member of the immunoglobulin superfamily molecules, which is involved in cell-cell adhesion. TSLC1 is connected to the actin cytoskeleton by DAL-1 (differentially expressed in adenocarcinoma of the lung-1, EPB41L3) and it directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large. Recent data suggest that aberrant promoter methylation is important for TSLC1 inactivation in lung carcinomas. However, little is known about the other two genes in this cascade, DAL-1 and MPP3. Thus, we investigated the expression and methylation patterns of these genes in lung cancer cell lines, primary lung carcinomas and nonmalignant lung tissue samples. By reverse transcription- polymerase chain reaction, loss of TSLC1 expression was observed in seven of 16 (44%) non-small-cell lung cancer (NSCLC) cell lines and in one of 11 (9%) small-cell lung cancer (SCLC) cell lines, while loss of DAL-1 expression was seen in 14 of 16 (87%) NSCLC cell lines and in four of 11 (36%) SCLC cell lines. By contrast, MPP3 expression was found in all tumor cell lines analysed. Similar results were obtained by microarray analysis. TSLC1 methylation was seen in 13 of 39 (33%) NSCLC cell lines, in one of 11 (9%) SCLC cell lines and in 100 of 268 (37%) primary NSCLCs. DAL-1 methylation was observed in 17 of 39 (44%) NSCLC cell lines, in three of 11 (27%) SCLC cell lines and in 147 of 268 (55%) primary NSCLCs. In tumors of NSCLC patients with stage II-III disease, DAL-1 methylation was seen at a statistically significant higher frequency compared to tumors of patients with stage I disease. A significant correlation between loss of expression and methylation of the genes in lung cancer cell lines was found. Overall, 65% of primary NSCLCs had either TSLC1 or DAL-1 methylated. Methylation of one of these genes was detected in 59% of NSCLC cell lines; however, in SCLC cell lines, methylation was much less frequently observed. The majority of nonmalignant lung tissue samples was not TSLC1 or DAL-1 methylated. Re-expression of TSLC1 and DAL-1 was seen after treatment of lung cancer cell lines with 5-aza-2′-deoxycytidine. Our results suggest that methylation of TSLC1 and/or DAL-1, leading to loss of their expression, is an important event in the pathogenesis of NSCLC.

Original languageEnglish (US)
Pages (from-to)959-968
Number of pages10
JournalOncogene
Volume25
Issue number6
DOIs
StatePublished - Feb 9 2006

Fingerprint

Methylation
Lung Neoplasms
Carcinoma
Cell Line
Lung
Non-Small Cell Lung Carcinoma
Genes
Small Cell Lung Carcinoma
Neoplasms
decitabine
Adenocarcinoma of lung
Microarray Analysis
Tumor Cell Line
Tumor Suppressor Genes
Actin Cytoskeleton
Cell Adhesion
Reverse Transcription
Drosophila
Immunoglobulins
Gene Expression

Keywords

  • DAL-1
  • Lung cancer
  • Methylation
  • MPP3
  • TSLC1
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Heller, G., Fong, K. M., Girard, L., Seidl, S., End-Pfützenreuter, A., Lang, G., ... Zöchbauer-Müller, S. (2006). Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene, 25(6), 959-968. https://doi.org/10.1038/sj.onc.1209115

Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. / Heller, G.; Fong, K. M.; Girard, L.; Seidl, S.; End-Pfützenreuter, A.; Lang, G.; Gazdar, A. F.; Minna, J. D.; Zielinski, C. C.; Zöchbauer-Müller, S.

In: Oncogene, Vol. 25, No. 6, 09.02.2006, p. 959-968.

Research output: Contribution to journalArticle

Heller, G, Fong, KM, Girard, L, Seidl, S, End-Pfützenreuter, A, Lang, G, Gazdar, AF, Minna, JD, Zielinski, CC & Zöchbauer-Müller, S 2006, 'Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas', Oncogene, vol. 25, no. 6, pp. 959-968. https://doi.org/10.1038/sj.onc.1209115
Heller G, Fong KM, Girard L, Seidl S, End-Pfützenreuter A, Lang G et al. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene. 2006 Feb 9;25(6):959-968. https://doi.org/10.1038/sj.onc.1209115
Heller, G. ; Fong, K. M. ; Girard, L. ; Seidl, S. ; End-Pfützenreuter, A. ; Lang, G. ; Gazdar, A. F. ; Minna, J. D. ; Zielinski, C. C. ; Zöchbauer-Müller, S. / Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. In: Oncogene. 2006 ; Vol. 25, No. 6. pp. 959-968.
@article{392e8585d5ea4c86b45dcbf32cfd2ec5,
title = "Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas",
abstract = "TSLC1 (tumor suppressor in lung cancer-1, IGSF4) encodes a member of the immunoglobulin superfamily molecules, which is involved in cell-cell adhesion. TSLC1 is connected to the actin cytoskeleton by DAL-1 (differentially expressed in adenocarcinoma of the lung-1, EPB41L3) and it directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large. Recent data suggest that aberrant promoter methylation is important for TSLC1 inactivation in lung carcinomas. However, little is known about the other two genes in this cascade, DAL-1 and MPP3. Thus, we investigated the expression and methylation patterns of these genes in lung cancer cell lines, primary lung carcinomas and nonmalignant lung tissue samples. By reverse transcription- polymerase chain reaction, loss of TSLC1 expression was observed in seven of 16 (44{\%}) non-small-cell lung cancer (NSCLC) cell lines and in one of 11 (9{\%}) small-cell lung cancer (SCLC) cell lines, while loss of DAL-1 expression was seen in 14 of 16 (87{\%}) NSCLC cell lines and in four of 11 (36{\%}) SCLC cell lines. By contrast, MPP3 expression was found in all tumor cell lines analysed. Similar results were obtained by microarray analysis. TSLC1 methylation was seen in 13 of 39 (33{\%}) NSCLC cell lines, in one of 11 (9{\%}) SCLC cell lines and in 100 of 268 (37{\%}) primary NSCLCs. DAL-1 methylation was observed in 17 of 39 (44{\%}) NSCLC cell lines, in three of 11 (27{\%}) SCLC cell lines and in 147 of 268 (55{\%}) primary NSCLCs. In tumors of NSCLC patients with stage II-III disease, DAL-1 methylation was seen at a statistically significant higher frequency compared to tumors of patients with stage I disease. A significant correlation between loss of expression and methylation of the genes in lung cancer cell lines was found. Overall, 65{\%} of primary NSCLCs had either TSLC1 or DAL-1 methylated. Methylation of one of these genes was detected in 59{\%} of NSCLC cell lines; however, in SCLC cell lines, methylation was much less frequently observed. The majority of nonmalignant lung tissue samples was not TSLC1 or DAL-1 methylated. Re-expression of TSLC1 and DAL-1 was seen after treatment of lung cancer cell lines with 5-aza-2′-deoxycytidine. Our results suggest that methylation of TSLC1 and/or DAL-1, leading to loss of their expression, is an important event in the pathogenesis of NSCLC.",
keywords = "DAL-1, Lung cancer, Methylation, MPP3, TSLC1, Tumor suppressor gene",
author = "G. Heller and Fong, {K. M.} and L. Girard and S. Seidl and A. End-Pf{\"u}tzenreuter and G. Lang and Gazdar, {A. F.} and Minna, {J. D.} and Zielinski, {C. C.} and S. Z{\"o}chbauer-M{\"u}ller",
year = "2006",
month = "2",
day = "9",
doi = "10.1038/sj.onc.1209115",
language = "English (US)",
volume = "25",
pages = "959--968",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas

AU - Heller, G.

AU - Fong, K. M.

AU - Girard, L.

AU - Seidl, S.

AU - End-Pfützenreuter, A.

AU - Lang, G.

AU - Gazdar, A. F.

AU - Minna, J. D.

AU - Zielinski, C. C.

AU - Zöchbauer-Müller, S.

PY - 2006/2/9

Y1 - 2006/2/9

N2 - TSLC1 (tumor suppressor in lung cancer-1, IGSF4) encodes a member of the immunoglobulin superfamily molecules, which is involved in cell-cell adhesion. TSLC1 is connected to the actin cytoskeleton by DAL-1 (differentially expressed in adenocarcinoma of the lung-1, EPB41L3) and it directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large. Recent data suggest that aberrant promoter methylation is important for TSLC1 inactivation in lung carcinomas. However, little is known about the other two genes in this cascade, DAL-1 and MPP3. Thus, we investigated the expression and methylation patterns of these genes in lung cancer cell lines, primary lung carcinomas and nonmalignant lung tissue samples. By reverse transcription- polymerase chain reaction, loss of TSLC1 expression was observed in seven of 16 (44%) non-small-cell lung cancer (NSCLC) cell lines and in one of 11 (9%) small-cell lung cancer (SCLC) cell lines, while loss of DAL-1 expression was seen in 14 of 16 (87%) NSCLC cell lines and in four of 11 (36%) SCLC cell lines. By contrast, MPP3 expression was found in all tumor cell lines analysed. Similar results were obtained by microarray analysis. TSLC1 methylation was seen in 13 of 39 (33%) NSCLC cell lines, in one of 11 (9%) SCLC cell lines and in 100 of 268 (37%) primary NSCLCs. DAL-1 methylation was observed in 17 of 39 (44%) NSCLC cell lines, in three of 11 (27%) SCLC cell lines and in 147 of 268 (55%) primary NSCLCs. In tumors of NSCLC patients with stage II-III disease, DAL-1 methylation was seen at a statistically significant higher frequency compared to tumors of patients with stage I disease. A significant correlation between loss of expression and methylation of the genes in lung cancer cell lines was found. Overall, 65% of primary NSCLCs had either TSLC1 or DAL-1 methylated. Methylation of one of these genes was detected in 59% of NSCLC cell lines; however, in SCLC cell lines, methylation was much less frequently observed. The majority of nonmalignant lung tissue samples was not TSLC1 or DAL-1 methylated. Re-expression of TSLC1 and DAL-1 was seen after treatment of lung cancer cell lines with 5-aza-2′-deoxycytidine. Our results suggest that methylation of TSLC1 and/or DAL-1, leading to loss of their expression, is an important event in the pathogenesis of NSCLC.

AB - TSLC1 (tumor suppressor in lung cancer-1, IGSF4) encodes a member of the immunoglobulin superfamily molecules, which is involved in cell-cell adhesion. TSLC1 is connected to the actin cytoskeleton by DAL-1 (differentially expressed in adenocarcinoma of the lung-1, EPB41L3) and it directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large. Recent data suggest that aberrant promoter methylation is important for TSLC1 inactivation in lung carcinomas. However, little is known about the other two genes in this cascade, DAL-1 and MPP3. Thus, we investigated the expression and methylation patterns of these genes in lung cancer cell lines, primary lung carcinomas and nonmalignant lung tissue samples. By reverse transcription- polymerase chain reaction, loss of TSLC1 expression was observed in seven of 16 (44%) non-small-cell lung cancer (NSCLC) cell lines and in one of 11 (9%) small-cell lung cancer (SCLC) cell lines, while loss of DAL-1 expression was seen in 14 of 16 (87%) NSCLC cell lines and in four of 11 (36%) SCLC cell lines. By contrast, MPP3 expression was found in all tumor cell lines analysed. Similar results were obtained by microarray analysis. TSLC1 methylation was seen in 13 of 39 (33%) NSCLC cell lines, in one of 11 (9%) SCLC cell lines and in 100 of 268 (37%) primary NSCLCs. DAL-1 methylation was observed in 17 of 39 (44%) NSCLC cell lines, in three of 11 (27%) SCLC cell lines and in 147 of 268 (55%) primary NSCLCs. In tumors of NSCLC patients with stage II-III disease, DAL-1 methylation was seen at a statistically significant higher frequency compared to tumors of patients with stage I disease. A significant correlation between loss of expression and methylation of the genes in lung cancer cell lines was found. Overall, 65% of primary NSCLCs had either TSLC1 or DAL-1 methylated. Methylation of one of these genes was detected in 59% of NSCLC cell lines; however, in SCLC cell lines, methylation was much less frequently observed. The majority of nonmalignant lung tissue samples was not TSLC1 or DAL-1 methylated. Re-expression of TSLC1 and DAL-1 was seen after treatment of lung cancer cell lines with 5-aza-2′-deoxycytidine. Our results suggest that methylation of TSLC1 and/or DAL-1, leading to loss of their expression, is an important event in the pathogenesis of NSCLC.

KW - DAL-1

KW - Lung cancer

KW - Methylation

KW - MPP3

KW - TSLC1

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=32544443054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544443054&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1209115

DO - 10.1038/sj.onc.1209115

M3 - Article

C2 - 16205641

AN - SCOPUS:32544443054

VL - 25

SP - 959

EP - 968

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 6

ER -